

3-1-2007

Distribution of the HIV resistance CCR5- Δ 32 allele among Egyptians and Syrians

Abdel Halim Salem
Center for BioModular Multi-Scale Systems

Mark A. Batzer
Center for BioModular Multi-Scale Systems

Follow this and additional works at: https://repository.lsu.edu/biosci_pubs

Recommended Citation

Salem, A., & Batzer, M. (2007). Distribution of the HIV resistance CCR5- Δ 32 allele among Egyptians and Syrians. *Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis*, 616 (1-2), 175-180. <https://doi.org/10.1016/j.mrfmmm.2006.11.024>

This Article is brought to you for free and open access by the Department of Biological Sciences at LSU Scholarly Repository. It has been accepted for inclusion in Faculty Publications by an authorized administrator of LSU Scholarly Repository. For more information, please contact ir@lsu.edu.

Distribution of the HIV resistance CCR5- Δ 32 allele among Egyptians and Syrians

Abdel-Halim Salem^{a,b}, Mark A. Batzer^{a,*}

^a Department of Biological Sciences, Biological Computation and Visualization Center, Center for Bio-Modular Multiscale Systems, Louisiana State University, 202 Life Sciences Building, Baton Rouge, LA 70803, United States

^b Department of Anatomy, Faculty of Medicine, Suez Canal University, Ismailia, Egypt

Available online 12 December 2006

Abstract

A mutant allele of the β -chemokine receptor gene CCR5 bearing a 32-basepair (bp) deletion that prevents cell invasion by the primary transmitting strain of HIV-1 has recently been characterized. Individuals homozygous for the mutation are resistant to infection, even after repeated high-risk exposure, but this resistance appears not absolute, as isolated cases of HIV-positive deletion homozygotes are emerging. The consequence of the heterozygous state is not clear, but it may delay the progression to AIDS in infected individuals. In order to evaluate the frequency distribution of CCR5- Δ 32 polymorphism among Egyptians, a total of 200 individuals (154 from Ismailia and 46 from Sinai) were tested. Only two heterozygous individuals from Ismailia carried the CCR5- Δ 32 allele (0.6%), and no homozygous (Δ 32/ Δ 32) individuals were detected among the tested samples. The presence of the CCR5- Δ 32 allele among Egyptians may be attributed to the admixture with people of European descent. Thus we conclude that the protective deletion CCR5- Δ 32 is largely absent in the Egyptian population.

© 2006 Elsevier B.V. All rights reserved.

Keywords: Human immunodeficiency virus type 1; Chemokine receptor; Polymorphisms

1. Introduction

A mutant allele of the β -chemokine receptor gene CCR5 bearing a 32-basepair (bp) deletion that prevents cell invasion by the primary transmitting strain of HIV-1 has recently been characterized [1–3]. Individuals homozygous for the mutation are resistant to infection, even after repeated high-risk exposure [1,4], but this resistance appears not absolute, as isolated cases of HIV-positive deletion homozygotes are emerging [5]. There is little information regarding human immunodeficiency virus (HIV) in Egypt. Among IV drug users,

a high risk group, the prevalence of HIV infection has already reached 8% in Cairo as of 1994 [6]. HIV infection levels declined between 1987 and 1993 in Cairo among male sexually transmitted disease (STD) patients. In 1987–1988, 0.7% were HIV positive; in 1993, 0.3% were infected. In 1994, there was no evidence of infection among STD patients attending STD clinics in Alexandria and Assiut [6–9]. The estimated percentage of adults living with HIV/AIDS in Egypt at the end of 1999 was 0.02% [8].

Chemokine receptors are cell surface proteins that bind small peptides called chemokines [10]. Chemokines can be classified into three groups based on the number and location of conserved cysteines: C, CC, and CXC. Chemokine receptors are grouped into families on the basis of the chemokine ligands they bind: CC, CXC, or both. The chemokine receptor CCR5 is encoded by

* Corresponding author. Tel.: +1 225 578 7102;

fax: +1 225 578 7113.

E-mail address: mbatzer@lsu.edu (M.A. Batzer).

the CMKBR gene located on the p21.3 region of human chromosome 3 [11]. The chemokine receptor gene CCR5 has become the object of intense interest since the discovery of its role in the entry of human immunodeficiency virus type 1 (HIV-1) into human CD4-positive cells [12,13]. The CCR5 gene product is a member of the seven-transmembrane, G-protein-coupled receptor family [14,15] which, in response to their normal β -chemokine ligands, is involved in the chemotaxis of leucocytes towards sites of inflammation [16]. CCR5 also mediates the entry into cells of the M-tropic strain of HIV-1 that is the primary transmitting form of the virus [17–21].

Almost simultaneously with the findings of the HIV coreceptors, a mutation in the gene that encodes CCR5 was reported that confers a high degree of resistance to HIV infection *in vitro* and *in vivo* [1,4]. This mutation, termed $\Delta 32$, consists in a 32 bp deletion that occurs at a site of a repeat motif in the CCR5 gene and results in a frameshift in the coding sequence that produces a non-functional protein, and as a result it is not expressed in the cell membrane [22]. It was believed that individuals with homozygous mutant genotype ($\Delta 32/\Delta 32$) were 100% resistant to HIV infection, at least with M-tropic strains, that use the CCR5 molecule as co-receptors. However, there have been reports of HIV infection in two individuals who are homozygous for the mutant allele ($\Delta 32/\Delta 32$) [5]. These infections could have occurred with T-tropic strains that use the CXCR4 molecule as coreceptors to enter the target cells. It has been difficult to establish if the CCR5/ $\Delta 32$ genotype confers any degree of resistance to infection. HIV-infected individuals heterozygous for CCR5- $\Delta 32$ have about a 2-year delay in progression to AIDS compared with HIV infected individuals who do not carry the $\Delta 32$ polymorphism [23–25]. Although the studies on these aspects of disease progression are contradictory [2,3,23,26].

The global distribution of the CCR5- $\Delta 32$ alleles among diverse human populations is widely variable. The CCR5- $\Delta 32$ allele is more prevalent in European populations and almost absent from Asian groups [2]. Within European populations a wide variation of 10–20% in CCR5- $\Delta 32$ frequency was observed with a gradient, uppermost at the north around the Baltic Sea down to the Mediterranean coast. It was inferred that most, if not all CCR5- $\Delta 32$ alleles originate from a single mutation event, and that this mutation event probably took place a few thousand years ago in Northeastern Europe [11]. The frequency of the mutation is 20.93% in Ashkenazi Jews [27,28]. In European-derived populations from the United States and Southern Europe, CCR5- $\Delta 32$ was observed at a frequency of 5–10%, but

decreased to 2–5% in Hispanic populations, throughout the Middle East or in the Indian continent. However, this allele is almost absent among African-Americans in whom admixture with people of European descent has been considerable [27]. In Asian populations, the CCR5- $\Delta 32$ alleles were absent among Japanese, Filipino, Korean, Chinese and Indian populations studied [29]. In Latin America, the CCR5- $\Delta 32$ was not detected among 32 individuals from Venezuela or in Amerindian groups [1,27]. The frequency of the allele reaches 5.3% in Columbia [30].

The age of the CCR5- $\Delta 32$ allele has been estimated to be between 700 and 3500 years old [31,32] with ancient DNA evidence suggesting an age of 2900 years old [33]. The high frequency of the CCR5- $\Delta 32$ allele in some populations is presumably the consequence of natural selection possibly driven by an increased resistance to an infectious agent [34–36]. The geographic spread of the CCR5- $\Delta 32$ resistance allele has recently been studied to determine how selection and dispersal have interacted during the history of the allele [37]. In the present study, the distribution of the CCR5- $\Delta 32$ allele among Egyptians and several other diverse human populations was analyzed.

2. Materials and methods

The human population samples used for this study have been described previously and were available from previous studies [38,39]. The samples studied were collected from unrelated individuals from six populations: Arabic countries (Egypt and Syria), European (German, Greek and Turkish Cypriots), sub-Saharan Africa (African American) under institutionally approved internal review board protocols with informed consent. DNA was prepared from blood leukocytes by standard methods [40]. The genotype determination was carried out as previously described [24]. The specific segment of CCR5 gene was amplified by polymerase chain reaction (PCR) using the following primers [30]: CCR5-F (5'-ACCAGATCTCAAAAAGAAGGTCT-3') and CCR5-R (5'-CATGATGGTGAAGATAAGCCTCAC-3'). PCR amplification was carried out in 25 μ l reactions containing 20–100 ng of template DNA, 40 pM of each oligonucleotide primers, 200 μ M dNTPs, in 50 mM KCl, 1.5 mM MgCl₂, 10 mM Tris-HCl (pH 8.4) and Taq DNA polymerase (1.25 Units). The reaction were subjected to 32 cycles: an initial denaturation of 150 s at 94 °C, 1 min denaturation at 94 °C, 1 min at the annealing temperature 55 °C, extension at 72 °C for 1 min. Following the amplification cycles a final extension was performed at 72 °C for 10 min. For analysis, 20 μ l of each sample was fractionated on a 3% agarose gel with 0.05 μ g/ml ethidium bromide. PCR products were directly visualized using UV fluorescence. For the wild type genotype (CCR5/CCR5), the PCR product was 225 bp while a product of 193 bp indi-




Fig. 1. Determination of CCR5 genotypes by agarose gel electrophoresis. DNA fragment patterns of persons with homozygous wild type (CCR5/CCR5) (lanes 1–4 and 8), homozygous 32 bp deletion ($\Delta 32/\Delta 32$) (lane 5) or heterozygous genotypes (CCR5/ $\Delta 32$) (lanes 6 and 7), are shown. Lane 9 is a negative control and lane 10 is 100 bp marker. The black arrows refer to the fragment size of 225 bp for wild type and 193 bp for mutant alleles.

cated a homozygous mutant ($\Delta 32/\Delta 32$). The presence of both fragments indicated a heterozygous genotype (CCR5/ $\Delta 32$) (Fig. 1). The allelic and genotypic frequencies were compared and differences evaluated using the chi square test for goodness of fit (χ^2). The significant deviation from Hardy–Weinberg equilibrium (HWE) was evaluated by the same test.

DNA sequencing was performed on gel purified PCR products that had been cloned using the TOPO-TA cloning vector (Invitrogen) using chain termination sequencing [41] on an Applied Biosystems 3100 automated DNA sequencer. The automated DNA sequencing was employed to confirm the authenticity of the amplified PCR products.

3. Results

The CCR5 genotype was determined by polymerase chain reaction (PCR) from six diverse population samples. As shown in Table 1, we found that 152 individuals from Egypt living in Ismailia were homozygous for the wild-type CCR5 allele and two were heterozygous for the CCR5- $\Delta 32$ allele, giving a CCR5- $\Delta 32$ allelic frequency of 0.006. None of the individuals tested was homozygous for the mutation ($\Delta 32/\Delta 32$). No mutant alleles were identified in 46 Egyptian individuals from the Sinai. Based on the allele frequencies it is possible to predict the genotype frequency considering that they follow the Hardy–Weinberg equilibrium. This means that the frequencies have a binomial distribution according to the following equation: $p^2 + 2pq + q^2 = 1$, where p and q are the allelic frequencies of CCR5 and $\Delta 32$, respectively, and p^2 , $2pq$ and q^2 are the genotype frequencies of CCR5/CCR5, CCR5/ $\Delta 32$, and $\Delta 32/\Delta 32$, respectively. No significant deviations from the Hardy–Weinberg equilibrium were observed. Table 1 shows the frequency of the CCR5- $\Delta 32$ allele in the populations analyzed here as well as selected populations from previous studies. The frequency of the CCR5- $\Delta 32$ allele was high among German Europeans (12.8%), moderate in Turkish individuals from Turkey (6.3%) and from Cyprus (3.2%). It is found at a very low frequency in Cyprus (Greek)

Table 1
CCR5 genotypes in diverse human populations

Population	No. of studied	CCR5/CCR5	CCR5/ $\Delta 32$	$\Delta 32/\Delta 32$
Egypt-Ismaïlia	154	152	2	0
Egypt-Sinai	46	46	0	0
Syria	69	68	1	0
Lebanon [31]	51	51	0	0
Saudi Arabia [27]	241	231	10	0
Saudi Arabia [31]	100	100	0	0
United Arab Emirates [56]	26	26	0	0
Yemen [27]	34	34	0	0
Sudan [56]	25	25	0	0
Kenya [27]	80	80	0	0
Nigeria [27]	111	110	1	0
African-American	87	85	2	0
German European	74	58	13	3
Turkey [11]	104	91	13	0
Cyprus (Turkish)	47	44	3	0
Cyprus (Greek)	56	55	1	0
Kuwait [42]	393	385	8	0
Syria [42]	106	103	3	0
Jordan [42]	52	52	0	0
Iraq [42]	13	13	0	0
Iran [42]	84	80	4	0
Russia [42]	176	133	43	0

Data from previous studies is denoted by the citations.

(0.9%) and is completely absent from populations of African origin except Nigerians and African Americans, where it is detected at very low frequency. Within the Arabic populations, the frequency of the mutant $\Delta 32$ allele reached its highest among Saudis 2.07% [27] and Iranians 2.38% [42]. In a previous study done by Stephens et al. [31], no mutant alleles were detected among 100 individuals from Saudi Arabia. By combining both studies together, the frequency of CCR5- $\Delta 32$ among Saudis drops to 1.5%. This frequency is still higher than any of the other Arabic countries (Table 1). The frequency of the CCR5- $\Delta 32$ was very low among Syrians (0.7%), Egyptians from Ismailia (0.6%) and is completely absent from individuals from Lebanon, Sudan, Yemen, the United Arab Emirates and Egyptians from the Sinai (Table 1). Our findings suggest that the CCR5- $\Delta 32$ allele is nearly absent from Arabic populations. However, the near absence of the CCR5 gene 32-bp deletion mutation does not preclude the existence of other polymorphisms of chemokine receptor genes associated with slower progression to AIDS within these populations.

4. Discussion

Despite the apparent resistance afforded by the CCR5- $\Delta 32$ mutation, protection against HIV-1 infection is not absolute, as evidenced by reports of HIV-1 infection among $\Delta 32/\Delta 32$ homozygotes [5,43,44]. Thus far, however, acquisition of HIV-1 infection in such individuals has been by the parenteral rather than mucosal route, suggesting utilization of the CXCR4 coreceptor by dual-tropic strains of HIV-1 among infected $\Delta 32$ homozygotes. Recently, it was demonstrated that HIV could use other chemokine receptors such as CCR2 and CCR3 as coreceptors [45]. Therefore, mutations in these molecules or in the chemokine receptor ligands might explain the resistance to HIV infection of some individuals. However, the mutation CCR2-64I was not associated with a resistant phenotype but rather with a delayed in disease progression [46]. Similarly, the polymorphism SDF-1-3' A reported in the α -chemokine SDF-1 was associated with delayed onset of AIDS related symptoms [47].

The general absence of CCR5- $\Delta 32$ in sub-Saharan Africa suggests a recent origin of the mutation in agreement with a variety of other age estimates [31–33], but also suggests that it is not a significant factor in the prevalence or transmission of HIV-1 within Africa. The high frequency of CCR5- $\Delta 32$ in Europe may indicate that it too has had a long term selective advantage against infectious diseases using CCR5 as entry cofac-

tors, as suggested previously [3,34–36]. Alternatively, this may be the result of a previously-neutral polymorphism whose selective advantage is just becoming apparent.

The high frequency of the CCR5- $\Delta 32$ allele in some populations could affect the epidemiology of the disease and the mean progression rate of HIV-positive individuals in these populations. It may also favor the emergence of strains that can bypass the CCR5 defect by using other coreceptors efficiently [18,20,48]. The uneven distribution of the genotype across geographic and racial groups may be related to some previous epidemic, restricted to Europe that led to a survival advantage among persons homozygous or heterozygous for the CCR5/ $\Delta 32$ genotype and resulted in a concentration of the CCR5/ $\Delta 32$ genotype in persons of European ancestry. The bubonic plague, which claimed the lives of 25–33% of Europeans during the Black Death from 1346 to 1352 and other large epidemics such as small pox have been used as examples to support this [49–53]. Thus, certain populations appear to have some increase in survival advantage in the current HIV epidemic. Conversely, populations with lower frequencies of the CCR5- $\Delta 32$ genotype might be expected to have a higher prevalence of HIV infection or a more rapid course of the epidemic. A greater risk for HIV infection has been found among African Americans than among European Americans from the United States, when known risk factors, including social class, were controlled [54]. The prevalence of the CCR5- $\Delta 32$ allele is lower in African Americans than in European Americans. While increasing HIV prevalence in parts of Asia and Africa may be attributed to social and demographic factors, as well as differences in the phenotype of circulating viruses [55], the racial distribution of HIV risk raises the possibility that differences in the distribution of the CCR5- $\Delta 32$ allele or other heritable host factors/mutations may influence the rate of transmission or the speed of the epidemic in different racial groups.

In the Arabic countries, the frequency of the mutant allele CCR5- $\Delta 32$ is very low and probably derived from admixture with the populations of European descent rather than as a result of parallel independent mutations. Future studies are needed to study the chromosomal haplotypes carrying this mutation and the mutation frequency among the rest of the Arabic populations.

Acknowledgements

This research was supported by the Louisiana Board of Regents Governor's Biotechnology Initiative GBI (2002–2005) (M.A.B.), National Science Foundation

EPS-0346411 (M.A.B.) and the State of Louisiana Board of Regents Support Fund (M.A.B.).

References

- [1] R. Liu, W.A. Paxton, S. Choe, D. Ceradini, S.R. Martin, R. Horuk, M.E. MacDonald, H. Stuhlmann, R.A. Koup, N.R. Landau, Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection, *Cell* 86 (1996) 367–377.
- [2] M. Samson, F. Libert, B.J. Doranz, J. Rucker, C. Liesnard, C.M. Farber, S. Saragosti, C. Lapoumeroulie, J. Cognaux, C. Forceville, G. Muyldermans, C. Verhofstede, G. Burtonboy, M. Georges, T. Imai, S. Rana, Y. Yi, R.J. Smyth, R.G. Collman, R.W. Doms, G. Vassart, M. Parmentier, Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene, *Nature* 382 (1996) 722–725.
- [3] M. Dean, M. Carrington, C. Winkler, G.A. Huttley, M.W. Smith, R. Allikmets, J.J. Goedert, S.P. Buchbinder, E. Vittinghoff, E. Gomperts, S. Donfield, D. Vlahov, R. Kaslow, A. Saah, C. Rinaldo, R. Detels, S.J. O'Brien, Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study, *Science* 273 (1996) 1856–1862.
- [4] W.A. Paxton, S.R. Martin, D. Tse, T.R. O'Brien, J. Skurnick, N.L. VanDevanter, N. Padian, J.F. Braun, D.P. Kotler, S.M. Wolinsky, R.A. Koup, Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure, *Nat. Med.* 2 (1996) 412–417.
- [5] R. Biti, R. Ffrench, J. Young, B. Bennetts, G. Stewart, T. Liang, HIV-1 infection in an individual homozygous for the CCR5 deletion allele, *Nat. Med.* 3 (1997) 252–253.
- [6] M.A. Hasan, A.B. Farag, M.A. Ismail, AIDS and intravenous drug users in Egypt, in: *Proceedings of the Tenth International Conference on AIDS, Yokohama, Japan, 1994*.
- [7] D.M. Watts, N.T. Constantine, M.F. Sheba, M. Kamal, J.D. Callahan, M.E. Kilpatrick, Prevalence of HIV infection and AIDS in Egypt over 4 years of surveillance (1986–1990), *J. Trop. Med. Hyg.* 96 (1993) 113–117.
- [8] P.N. Shrestha, Forthcoming WER Global Update of AIDS Cases Reported to WHO, WHO/EMRO/ASD, 1999.
- [9] A.S. Sadek, M. Bassily, M. Bishai, Human immunodeficiency virus and other sexually transmitted pathogens among std patients in Cairo, Egypt, in: *Proceedings of the VII International Conference on AIDS, Florence, Italy, 1991*.
- [10] P.M. Murphy, Chemokine receptors: structure, function and role in microbial pathogenesis, *Cytokine Growth Factor Rev.* 7 (1996) 47–64.
- [11] F. Libert, P. Cochaux, G. Beckman, M. Samson, M. Aksenova, A. Cao, A. Czeizel, M. Claustres, C. de laRua, M. Ferrari, C. Ferrec, G. Glover, B. Grinde, S. Guran, V. Kucinskias, J. Lavinha, B. Mercier, G. Ogur, L. Peltonen, C. Rosatelli, M. Schwartz, V. Spitsyn, L. Timar, L. Beckman, G. Vassart, et al., The *deltaccr5* mutation conferring protection against HIV-1 in Caucasian populations has a single and recent origin in Northeastern Europe, *Hum. Mol. Genet.* 7 (1998) 399–406.
- [12] C.M. Hill, D.R. Littman, Natural resistance to HIV? *Nature* 382 (1996) 668–669.
- [13] A.S. Fauci, Resistance to HIV-1 infection: it's in the genes, *Nat. Med.* 2 (1996) 966–967.
- [14] K. Neote, D. DiGregorio, J.Y. Mak, R. Horuk, T.J. Schall, Molecular cloning, functional expression, and signaling characteristics of a C-C chemokine receptor, *Cell* 72 (1993) 415–425.
- [15] M. Samson, O. Labbe, C. Mollereau, G. Vassart, M. Parmentier, Molecular cloning and functional expression of a new human CC-chemokine receptor gene, *Biochemistry* 35 (1996) 3362–3367.
- [16] P.M. Murphy, The molecular biology of leukocyte chemoattractant receptors, *Annu. Rev. Immunol.* 12 (1994) 593–633.
- [17] G. Alkhatib, C. Combadiere, C.C. Broder, Y. Feng, P.E. Kennedy, P.M. Murphy, E.A. Berger, CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1, *Science* 272 (1996) 1955–1958.
- [18] H. Choe, M. Farzan, Y. Sun, N. Sullivan, B. Rollins, P.D. Ponath, L. Wu, C.R. Mackay, G. LaRosa, W. Newman, N. Gerard, C. Gerard, J. Sodroski, The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates, *Cell* 85 (1996) 1135–1148.
- [19] H. Deng, R. Liu, W. Ellmeier, S. Choe, D. Unutmaz, M. Burkhart, P. Di Marzio, S. Marmon, R.E. Sutton, C.M. Hill, C.B. Davis, S.C. Peiper, T.J. Schall, D.R. Littman, N.R. Landau, Identification of a major co-receptor for primary isolates of HIV-1, *Nature* 381 (1996) 661–666.
- [20] B.J. Doranz, J. Rucker, Y. Yi, R.J. Smyth, M. Samson, S.C. Peiper, M. Parmentier, R.G. Collman, R.W. Doms, A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors, *Cell* 85 (1996) 1149–1158.
- [21] T. Dragic, V. Litwin, G.P. Allaway, S.R. Martin, Y. Huang, K.A. Nagashima, C. Cayanan, P.J. Maddon, R.A. Koup, J.P. Moore, W.A. Paxton, HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5, *Nature* 381 (1996) 667–673.
- [22] J.M. McNicholl, D.K. Smith, S.H. Qari, T. Hodge, Host genes and HIV: the role of the chemokine receptor gene CCR5 and its allele, *Emerg. Infect. Dis.* 3 (1997) 261–271.
- [23] Y. Huang, W.A. Paxton, S.M. Wolinsky, A.U. Neumann, L. Zhang, T. He, S. Kang, D. Ceradini, Z. Jin, K. Yazdanbakhsh, K. Kunstman, D. Erickson, E. Dragon, N.R. Landau, J. Phair, D.D. Ho, R.A. Koup, The role of a mutant CCR5 allele in HIV-1 transmission and disease progression, *Nat. Med.* 2 (1996) 1240–1243.
- [24] N.L. Michael, G. Chang, L.G. Louie, J.R. Mascola, D. Dondero, D.L. Bix, H.W. Sheppard, The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression, *Nat. Med.* 3 (1997) 338–340.
- [25] J. Eugen-Olsen, A.K. Iversen, P. Garred, U. Koppelhus, C. Pedersen, T.L. Benfield, A.M. Sorensen, T. Katzenstein, E. Dickmeiss, J. Gerstoft, P. Skinhoj, A. Svejgaard, J.O. Nielsen, B. Hofmann, Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS-free survival and slower CD4 T-cell decline in a cohort of HIV-seropositive individuals, *AIDS* 11 (1997) 305–310.
- [26] T.L. Hoffman, R.R. MacGregor, H. Burger, R. Mick, R.W. Doms, R.G. Collman, CCR5 genotypes in sexually active couples discordant for human immunodeficiency virus type 1 infection status, *J. Infect. Dis.* 176 (1997) 1093–1096.
- [27] J.J. Martinson, N.H. Chapman, D.C. Rees, Y.T. Liu, J.B. Clegg, Global distribution of the CCR5 gene 32-basepair deletion, *Nat. Genet.* 16 (1997) 100–103.
- [28] M. Magierowska, V. Lepage, L. Boubnova, C. Carcassi, D. de Juan, S. Djoulah, F. El Chenawi, N. Grunnet, L. Halle, R. Ivanova, M. Jungerman, E. Naumova, G. Petrany, A. Sonnerborg, C. Stavropoulos, E. Thorsby, A. Vu-Trieu, P. Debre, I. Theodorou,

- D. Charron, Distribution of the CCR5 gene 32 base pair deletion and SDF1-3'A variant in healthy individuals from different populations, *Immunogenetics* 48 (1998) 417–419.
- [29] Y. Lu, V.R. Nerurkar, W.M. Dashwood, C.L. Woodward, S. Ablan, C.M. Shikuma, A. Grandinetti, H. Chang, H.T. Nguyen, Z. Wu, Y. Yamamura, W.O. Boto, A. Merriwether, T. Kurata, R. Detels, R. Yanagihara, Genotype and allele frequency of a 32-base pair deletion mutation in the CCR5 gene in various ethnic groups: absence of mutation among Asians and Pacific Islanders, *Int. J. Infect. Dis.* 3 (1999) 186–191.
- [30] F.J. Diaz, J.A. Vega, P.J. Patino, G. Bedoya, J. Nagles, C. Villegas, R. Vesga, M.T. Rugeles, Frequency of CCR5 delta-32 mutation in human immunodeficiency virus (HIV)-seropositive and HIV-exposed seronegative individuals and in general population of Medellin, Colombia, *Mem. Inst. Oswaldo Cruz* 95 (2000) 237–242.
- [31] J.C. Stephens, D.E. Reich, D.B. Goldstein, H.D. Shin, M.W. Smith, M. Carrington, C. Winkler, G.A. Huttley, R. Allikmets, L. Schriml, B. Gerrard, M. Malasky, M.D. Ramos, S. Morlot, M. Tzetzis, C. Oddoux, F.S. di Giovine, G. Nasioulas, D. Chandler, M. Aseev, M. Hanson, L. Kalaydjieva, D. Glavac, P. Gasparini, M. Dean, et al., Dating the origin of the CCR5-Delta32 AIDS-resistance allele by the coalescence of haplotypes, *Am. J. Hum. Genet.* 62 (1998) 1507–1515.
- [32] M. Slatkin, Simulating genealogies of selected alleles in a population of variable size, *Genet. Res.* 78 (2001) 49–57.
- [33] S. Hummel, D. Schmidt, B. Kremeyer, B. Herrmann, M. Oppermann, Detection of the CCR5-Delta32 HIV resistance gene in bronze age skeletons, *Genes Immunol.* 6 (2005) 371–374.
- [34] E. de Silva, M.P. Stumpf, HIV and the CCR5-Delta32 resistance allele, *FEMS Microbiol. Lett.* 241 (2004) 1–12.
- [35] M.P. Stumpf, H.M. Wilkinson-Herbots, Allelic histories: positive selection on a HIV-resistance allele, *Trends Ecol. Evol.* 19 (2004) 166–168.
- [36] A.P. Galvani, J. Novembre, The evolutionary history of the CCR5-Delta32 HIV-resistance mutation, *Microbes Infect.* 7 (2005) 302–309.
- [37] J. Novembre, A.P. Galvani, M. Slatkin, The geographic spread of the CCR5 Delta32 HIV-resistance allele, *PLoS Biol.* 3 (2005) e339.
- [38] M. Stoneking, J.J. Fontius, S.L. Clifford, H. Soodyall, S.S. Arcot, N. Saha, T. Jenkins, M.A. Tahir, P.L. Deininger, M.A. Batzer, Alu insertion polymorphisms and human evolution: evidence for a larger population size in Africa, *Genome Res.* 7 (1997) 1061–1071.
- [39] A.H. Salem, D.A. Ray, M.A. Batzer, Identity by descent and DNA sequence variation of human SINE and LINE elements, *Cytogenet. Genome Res.* 108 (2005) 63–72.
- [40] J. Sambrook, E.F. Fritsch, T. Maniatis, *Molecular Cloning: A laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.
- [41] F. Sanger, S. Nicklen, A.R. Coulson, DNA sequencing with chain-terminating inhibitors, *Proc. Natl. Acad. Sci. U.S.A.* 74 (1977) 5463–5467.
- [42] A. Voevodin, E. Samilchuk, S. Dashti, A survey for 32 nucleotide deletion in the CCR-5 chemokine receptor gene (deltaccr-5) conferring resistance to human immunodeficiency virus type 1 in different ethnic groups and in chimpanzees, *J. Med. Virol.* 55 (1998) 147–151.
- [43] T.R. O'Brien, C. Winkler, M. Dean, J.A. Nelson, M. Carrington, N.L. Michael, G.C. White, 2nd HIV-1 infection in a man homozygous for CCR5 delta 32, *Lancet* 349 (1997) 1219.
- [44] I. Theodorou, L. Meyer, M. Magierowska, C. Katlama, C. Rouzioux, HIV-1 infection in an individual homozygous for CCR5 delta 32. Seroco Study Group, *Lancet* 349 (1997) 1219–1220.
- [45] E.A. Berger, P.M. Murphy, J.M. Farber, Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease, *Annu. Rev. Immunol.* 17 (1999) 657–700.
- [46] M.W. Smith, M. Dean, M. Carrington, C. Winkler, G.A. Huttley, D.A. Lomb, J.J. Goedert, T.R. O'Brien, L.P. Jacobson, R. Kaslow, S. Buchbinder, E. Vittinghoff, D. Vlahov, K. Hoots, M.W. Hilgartner, S.J. O'Brien, Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study, *Science* 277 (1997) 959–965.
- [47] C. Winkler, W. Modi, M.W. Smith, G.W. Nelson, X. Wu, M. Carrington, M. Dean, T. Honjo, K. Tashiro, D. Yabe, S. Buchbinder, E. Vittinghoff, J.J. Goedert, T.R. O'Brien, L.P. Jacobson, R. Detels, S. Donfield, A. Willoughby, E. Gomperts, D. Vlahov, J. Phair, S.J. O'Brien, Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), *Science* 279 (1998) 389–393.
- [48] H.K. Deng, D. Unutmaz, V.N. KewalRamani, D.R. Littman, Expression cloning of new receptors used by simian and human immunodeficiency viruses, *Nature* 388 (1997) 296–300.
- [49] A.S. Lalani, J. Masters, W. Zeng, J. Barrett, R. Pannu, H. Everett, C.W. Arendt, G. McFadden, Use of chemokine receptors by poxviruses, *Science* 286 (1999) 1968–1971.
- [50] A.P. Galvani, M. Slatkin, Evaluating plague and smallpox as historical selective pressures for the CCR5-delta 32 HIV-resistance allele, *Proc. Natl. Acad. Sci. U.S.A.* 100 (2003) 15276–15279.
- [51] R.E. Lenski, Evolution of plague virulence, *Nature* 334 (1988) 473–474.
- [52] C. McEvedy, The bubonic plague, *Sci. Am.* 258 (1988) 118–123.
- [53] W. Klitz, C. Brautbar, A.M. Schito, L.F. Barcellos, J.R. Oksenberg, Evolution of the CCR5 Delta32 mutation based on haplotype variation in Jewish and Northern European population samples, *Hum. Immunol.* 62 (2001) 530–538.
- [54] P.J. Easterbrook, J.S. Chmiel, D.R. Hoover, A.J. Saah, R.A. Kaslow, L.A. Kingsley, R. Detels, Racial and ethnic differences in human immunodeficiency virus type 1 (HIV-1) seroprevalence among homosexual and bisexual men. The Multicenter AIDS Cohort Study, *Am. J. Epidemiol.* 138 (1993) 415–429.
- [55] L.E. Soto-Ramirez, B. Renjifo, M.F. McLane, R. Marlink, C. O'Hara, R. Suthent, C. Wasi, P. Vithayasai, V. Vithayasai, C. Apichartpiyakul, P. Auewarakul, V. Pena Cruz, D.S. Chui, R. Osathanondh, K. Mayer, T.H. Lee, M. Essex, HIV-1 Langerhans' cell tropism associated with heterosexual transmission of HIV, *Science* 271 (1996) 1291–1293.
- [56] B. Su, G. Sun, D. Lu, J. Xiao, F. Hu, R. Chakraborty, R. Deka, L. Jin, Distribution of three HIV-1 resistance-conferring polymorphisms (SDF1-3'A, CCR2-641, and CCR5-delta32) in global populations, *Eur. J. Hum. Genet.* 8 (2000) 975–979.